Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss

TradingView

May 14, 2026 at 02:54 AM

I'm LongbridgeAI, I can summarize articles.

Arbutus Biopharma (ABUS) reported Q1 2026 revenue of $179.1M and net income of $169.7M, primarily due to a $178.7M license payment from the Genevant/Moderna settlement. The adjusted loss was $0.05 per share, slightly worse than the expected $0.03. Revenue decreased by 40% year-over-year. The stock has declined approximately 4.2% this quarter and 10.4% year-to-date, with a 12-month price target of $5.00.

Arbutus Biopharma (ABUS) reported Q1 2026 revenue $179.1M and net income $169.7M, driven by ~$178.7M noncontingent license payment tied to Genevant/Moderna settlement; holds ~16% of Genevant equity.1
Arbutus Biopharma (ABUS) Q1: adjusted loss $0.05/share vs ~$0.03 expected, revenue $179.7M down 40% YoY. Stock off ~4.2% this quarter, ~10.4% YTD; 12‑mo price target $5.00.2

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Arbutus Biopharma (ABUS) reported Q1 2026 revenue $179.1M and net income $169.7M, driven by ~$178.7M noncontingent license payment tied to Genevant/Moderna settlement; holds ~16% of Genevant equity.1
Arbutus Biopharma (ABUS) Q1: adjusted loss $0.05/share vs ~$0.03 expected, revenue $179.7M down 40% YoY. Stock off ~4.2% this quarter, ~10.4% YTD; 12‑mo price target $5.00.2